How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Viral Vector and Vaccine Market
- By Vector Type: Adenoviral Vectors, Lentiviral Vectors, Adeno-Associated Viral (AAV) Vectors, Retroviral Vectors, Herpes Simplex Virus (HSV) Vectors
- By Vaccine Type: Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, mRNA Vaccines, Viral Vector Vaccines
- By Application: Gene Therapy, Cancer Immunotherapy, Infectious Disease Prevention, Rare Genetic Disorders, Autoimmune Diseases
- By End User: Hospitals and Clinics, Research and Academic Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Diagnostic Laboratories
- By Production Technology: Cell Culture-Based Production, Egg-Based Production, Recombinant DNA Technology, Synthetic Biology Platforms, Fermentation Technology
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Adenoviral Vectors leads By Vector Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 307 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.186 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.194 →
Full report · locked preview
Everything inside the Viral Vector and Vaccine Market report
A complete, evidence-based study - 12 chapters and 129 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Vector Type 5
Vaccine Type 5
Application 5
End User 5
Production Technology 5
Companies profiled
Johnson & Johnson
Merck & Co. Inc.
AstraZeneca
Pfizer Inc.
Sanofi
GlaxoSmithKline (GSK)
Moderna Inc.
Novavax Inc.
Bavarian Nordic
CureVac N.V.
Sino Biopharmaceutical Limited
CanSino Biologics Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Johnson & Johnson
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Merck & Co. Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →AstraZeneca
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Sanofi
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →GlaxoSmithKline (GSK)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Moderna Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Novavax Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Bavarian Nordic
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →CureVac N.V.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Sino Biopharmaceutical Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →CanSino Biologics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Bharat Biotech International Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Regenxbio Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Sorrento Therapeutics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,363M by 2033 · 6.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Adenoviral Vectors41.6
- Lentiviral Vectors11.4
- Adeno-Associated Viral (AAV) Vectors16.3
- Retroviral Vectors10.1
- Herpes Simplex Virus (HSV) Vectors20.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,276M → $1,958M · 5.5%
Europe$889.6M → $1,493M · 6.7%
Asia Pacific$812.2M → $1,323M · 6.3%
Latin America$502.8M → $851.1M · 6.8%
Middle East and Africa$386.8M → $617.4M · 6.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.382026
6.392027
6.402028
6.412029
6.422030
6.442031
6.442032
6.472033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Johnson & Johnson22.1
- Merck & Co. Inc.10.2
- AstraZeneca11.0
- Pfizer Inc.10.0
- Sanofi8.8
- GlaxoSmithKline (GSK)9.9
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Vector Type25.3%
Vaccine Type16.1%
Application11.2%
End User23.9%
Production Technology23.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.4
- Europe23.9
- Asia Pacific21.2
- Latin America13.6
- Middle East and Africa9.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Johnson & Johnson | 98 | 85 | 81 | 85 | 78 | 93 | 87 |
| Merck & Co. Inc. | 86 | 85 | 75 | 91 | 69 | 84 | 82 |
| AstraZeneca | 86 | 78 | 64 | 84 | 87 | 65 | 77 |
| Pfizer Inc. | 73 | 79 | 77 | 76 | 81 | 59 | 74 |
| Sanofi | 70 | 52 | 74 | 57 | 56 | 58 | 61 |
| GlaxoSmithKline (GSK) | 63 | 69 | 69 | 64 | 62 | 48 | 63 |
| Moderna Inc. | 45 | 41 | 42 | 66 | 44 | 59 | 50 |
| Novavax Inc. | 37 | 52 | 38 | 56 | 38 | 60 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Johnson & Johnson
- Merck & Co. Inc.
- AstraZeneca
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Johnson & Johnson | ✓ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Merck & Co. Inc. | ✓ | ◐ | ✓ | ✓ | ✓ | ✓ |
| AstraZeneca | ◐ | ◐ | ◐ | ◐ | ◐ | − |
| Pfizer Inc. | ◐ | ✓ | ✓ | ◐ | ✓ | − |
| Sanofi | ✓ | ◐ | ◐ | − | − | − |
| GlaxoSmithKline (GSK) | ◐ | ✓ | − | − | ◐ | ◐ |
| Moderna Inc. | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| Novavax Inc. | − | − | − | ◐ | − | ✓ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Johnson & Johnson87
2Merck & Co. Inc.82
3AstraZeneca77
4Pfizer Inc.74
5GlaxoSmithKline (GSK)63
6Sanofi61
7Moderna Inc.50
8Novavax Inc.47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Johnson & JohnsonMerck & Co. Inc.
Challenger2
Strong scale, closing on the leaders.
AstraZenecaPfizer Inc.
Contender2
Focused players with pockets of strength.
SanofiGlaxoSmithKline (GSK)
Niche2
Specialists in a single segment or region.
Moderna Inc.Novavax Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Vector Type in North America, then scale across Viral Vector and Vaccine Market — a $161M beachhead inside a $2.48B market.
Beachhead (SOM)$161Mobtainable near-term
Serviceable (SAM)$977Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Adenoviral Vectors
Best fit — highest urgency & budget in Vector Type.
Economic buyer81 fit
Lentiviral Vectors
Strong fit — clear ROI and a fast path to value.
End user66 fit
Adeno-Associated Viral (AAV) Vectors
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Vector Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Vaccine Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales49%
Partner / channel26%
Digital / self-serve19%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Vector Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Viral Vector and Vaccine Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified21%
Evaluation15%
Closed-won7%
$21.8KCAC
$116KLTV
5.3:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Viral Vector and Vaccine Market is a high-growth opportunity — $7.87B by 2033, compounding at 10.3%.
TAM · 2025$3.59Btoday
TAM · 2033$7.87Bforecast
CAGR10.3%2027–2033
Cumulative$49.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.87BTotal addressable market
SAM$2.84BServiceable available market
SOM$537MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.3% CAGR
Demand compounds through 2033, outpacing GDP across Vector Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Vector Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.87BLarge & growingTAM by 2033 at 10.3% CAGR
$2.84BServiceable nowreachable with today’s model
$537MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.14BBear6.7% CAGR
$7.87BBase10.3% CAGR
$10.1BBull13.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Vaccine Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Viral Vector and Vaccine Market — a $2.01B market by 2033. Plan: grow share from 8.0% to 15.3%.
Market size · 2033$2.01Btotal addressable
Market CAGR4.7%2027–2033
Target share15.3%from 8.0% today
Revenue ambition$308Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.0% | 15.3% | At risk |
| Revenue | $146M | $308M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 34.0% | 41.1% | On track |
| Customer retention | 91.1% | 94.7% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Vector Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Vaccine Type capability
A defensible second engine — invest in Vaccine Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Vector Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Vaccine Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $37M capacity & capability investment
- Greenlight bolt-on M&A in Vaccine Type
- Authorise North America expansion plan
- Fund R&D program for Vector Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Viral Vector and Vaccine Market conversation — a $8.06B market you can size, segment and defend in minutes.
Market size · 2033$8.06Btotal opportunity
Growth5.7%CAGR to 2033
Addressable buyers1,463+accounts in scope
Typical ROI7.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Vector Type
Goal Grow share in Vector Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.3×return on cost, year one
< 3 mopayback period
$78K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Johnson & JohnsonMerck & Co. Inc.AstraZenecaPfizer Inc.SanofiGlaxoSmithKline (GSK)Moderna Inc.Novavax Inc.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Viral Vector and Vaccine Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Viral Vector and Vaccine Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Viral Vector and Plasmid DNA Testing Service Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportViral Vector and Plasmid DNA Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportViral Vaccine Media Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportViral Vaccine Cell Culture Media Market
Market size, share, segmentation and regional forecast.
$557M market · 2025 base year
View reportViral Transport Media (VTM) Kits Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportViral Transport Media Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportViral Sign Sensor Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportViral Sample Preservation Solution Market
Market size, share, segmentation and regional forecast.
$549M market · 2025 base year
View reportViral RNA Extraction Kit Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportViral Pneumonia Treatment Drugs Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportViral Inactivation Kits Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportViral Gene Therapy Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.